Stimulus-Specific Effects of Endotoxin on Superoxide Production by Rabbit Polymorphonuclear Leukocytes*

JAMES T. ROSENBAUM, M.D.,* AND HOLLY ENKEL, B.A.♭

*Oregon Health Sciences University, Portland, Oregon; ♭Kuzell Institute for Arthritis and Infectious Diseases, San Francisco, California

Received January 27, 1987

The release of superoxide (O2−) by polymorphonuclear leukocytes (PMN) is an important function that contributes to microbial death. Controversy exists as to the effect of bacterial endotoxin (lipopolysaccharide, or LPS) on the production of O2−. We have injected rabbits with 25 µg Escherichia coli LPS intravenously and studied PMN function 18 to 24 hours later. Relative to PMN from saline-injected controls, PMN from LPS-treated rabbits released markedly greater amounts of O2− in response to 10 ng/ml phorbol myristate acetate (PMA) as measured by nmol cytchrome C reduced in 20 minutes (40.8 ± 7.8 for LPS-treated PMN versus 10.1 ± 1.6 for control, p < 0.01). LPS injection, however, significantly reduced O2− release in response to C (complement) 5a (1.4 ± 0.6 nmole/20 minutes for LPS-treated PMN versus 5.6 ± 1.3 nmole/20 minutes for control, p < 0.01). O2− release in response to a third stimulus, n-formyl-methionyl-leucyl-phenylalanine (10−7 to 10−9 M), was not affected by LPS. O2− release in response to PMA was enhanced over a wide range of PMA concentrations (10 to 300 ng/ml). Kinetic studies over 30 minutes indicated that, after a brief initial latency in measurable response, LPS enhanced responsiveness to PMA at all time points observed. The reduced responsiveness to C5a corresponds to a previously reported down regulation of receptors for this ligand after intravenous LPS. The observations indicate that intravenous LPS can alter a critical function of PMN for at least 24 hours in a stimulus-specific manner.

INTRODUCTION

Studies on the effect of endotoxin (bacterial lipopolysaccharide, or LPS) on the production of superoxide by polymorphonuclear leukocytes (PMN) have yielded conflicting results. Guthrie and colleagues [1], for example, have reported that the exposure of human PMN to endotoxin in vitro enhances their capability to release superoxide in response to immune complexes, phorbol myristate acetate (PMA), or n-formyl-methionyl-leucyl-phenylalanine (FMLP). In contrast, Proctor [2] found that prior exposure of human PMN to LPS reduced their ability to release O2− in response to bacterial stimuli. Henricks and colleagues [3] used 18-hour incubations of PMN and LPS to characterize the effects of endotoxin on O2− release. These investigators found that LPS from Escherichia coli 0111B4 and from the polysaccharide-deficient mutant J5 enhanced O2− production when LPS itself was used as a stimulus. Using staphylococcus as a stimulus, however, LPS 0111B4 enhanced O2− release, while the LPS from J5 reduced it.

We have recently characterized the effects of intravenously injected endotoxin on PMN function in a rabbit model. We have previously reported that intravenously

Abbreviations: C5a: complement 5a FMLP: n-formyl-methionyl-leucyl-phenylalanine LPS: lipopolysaccharide PMA: phorbol myristate acetate PMN: polymorphonuclear leukocyte

*Presented in part at the Western Section AFCR, Carmel, CA, February 6, 1986

Address reprint requests to: James T. Rosenbaum, M.D., Oregon Health Sciences University, L329A, 3181 S.W. Sam Jackson Park Road, Portland OR 97201

Copyright © 1987 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.
injected endotoxin (1) inhibits the vascular permeability and PMN extravasation from blood vessels that is associated with a dermal reversed passive Arthus reaction [4]; (2) inhibits chemotaxis and degranulation in response to C (complement) 5a but not in response to FMLP [4,5]; and (3) down regulates the receptor for C5a while causing a marked increase in the number of receptors for FMLP [6].

Superoxide production plays an integral part in microbial killing by PMN and also contributes to inflammation. We have assessed the effects of intravenously injected endotoxin on the ability of rabbit PMN to release $O_2^-$. 

METHODS

**Animals**

Two-kilogram New Zealand White female rabbits were purchased from Animals West (Soquel, CA). They were housed in the animal care facilities of the Medical Research Institute of San Francisco and fed standard laboratory chow.

**Isolation of PMN**

Rabbit PMN were isolated from acid-citrate-dextrose anticoagulated blood obtained from the central ear artery, as we have previously described [4]. Thirty-four ml of blood plus 6 to 8 ml of anticoagulant were mixed with 8 ml of 6 percent (weight/volume) Dextran T500 (Pharmacia Fine Chemicals, Piscataway, NJ) in normal saline. After sedimenting for approximately 30 minutes, the supernatant was layered over 56 percent Percoll (Sigma Chemical Co., St. Louis, MO) and centrifuged at 450 g for 20 minutes. The erythrocyte/PMN pellet from this centrifugation was suspended for seven minutes in 40 ml of 8.3 percent (weight/volume) ammonium chloride (pH 7.2) to produce lysis of erythrocytes. The pellet of PMN was then washed twice with phosphate buffered saline (300 mM, pH = 7.2) (GIBCO, Grand Island, New York).

**Endotoxin**

*E. coli* LPS 055:B5 was purchased from RIBI Immunochem (Hamilton, MT). It was suspended in saline prior to use and stored at $-20^\circ$C. Control rabbits received sterile, pyrogen-free saline in volume comparable to that used for endotoxin injection.

**Superoxide Release Assay**

Rabbit PMN were suspended in a buffer of Hanks' balanced salt solution (GIBCO) plus 0.25 percent bovine serum albumin (Sigma Chemicals, St. Louis, MO) at a concentration of $5 \times 10^6$/ml. Stimuli in variable concentrations were added to the reaction mixture that included PMN and ferricytochrome C (Sigma) (0.08 mM in phosphate buffered saline, final concentration). The reaction was stopped after 20 minutes by placing the cells on ice for five minutes. Cells were removed by centrifugation at 2,000 rpm for five minutes and the reduction of ferricytochrome C was judged by the change in absorption at 550 nm [7]. The reduction of ferricytochrome C could be inhibited by including superoxide dismutase (Sigma) (20 ng/ml) in the reaction mixture. Data are expressed as the reduction of ferricytochrome C in response to stimulus minus the reduction in control reaction mixtures incubated in buffer alone. To control for day-to-day assay variability, each assay included PMN from one saline-injected rabbit and one endotoxin-injected rabbit. For kinetics experiments, cells were maintained at $37^\circ$C in a Perkin-Elmer spectrophotometer with
continuous stirring. Absorbance readings were made once per minute. Rabbit C5a was partially purified from zymosan (ICN Biochemicals, Cleveland, OH) activated rabbit serum through a combination of sizing and ion exchange column chromatography, as we have previously described [4]. The concentration used for superoxide release was 1 percent, roughly twofold greater than the optimal concentration for chemotaxis [5]. PMA was purchased from Sigma. FMLP was purchased from Peninsula Laboratories (San Carlos, CA), dissolved in dimethyl sulfoxide, and stored frozen at $-20^\circ$C.

**Statistics**

Data are expressed as mean ± SE and compared by the student's $t$-test.

**RESULTS**

Rabbits received 25 $\mu$g of LPS intravenously or a comparable volume of saline and were bled 18 to 24 hours later. As shown in Table 1, PMN from LPS-treated rabbits released significantly less $O_2^-$ in response to 1 percent C5a than PMN from saline-injected controls ($p < 0.01$). In marked contrast, PMN from LPS-treated rabbits released fourfold more $O_2^-$ in response to PMA (10 ng/ml) than PMN from control rabbits ($p < 0.01$). Both sets of PMN released $O_2^-$ comparably in response to FMLP ($10^{-7}$ M). The unstimulated release of $O_2^-$ was also comparable for the two groups (7.2 ± 1.4 nmol/20 minutes vs. 8.0 ± 1.8 nmol/20 minutes saline-treated versus LPS-treated PMN, respectively). Superoxide release was also studied at two lower concentrations of FMLP, $10^{-8}$ and $10^{-9}$ M. For three pairs of rabbit PMN at each concentration, there was no statistical difference in $O_2^-$ release (data not shown).

The increased capacity to release $O_2^-$ was evident at concentrations of PMA ranging from 10 to 300 ng/ml (Fig. 1). Increasing the PMA concentration from 100 to 300 ng/ml appeared to induce minimal additional release of $O_2^-$, suggesting that PMN had reached a plateau in responsiveness to PMA at a similar concentration, regardless of the prior in vivo exposure to endotoxin (Fig. 1). In the studies summarized in Fig. 1, PMN from saline-treated rabbits were more responsive to PMA (10 ng/ml) than the control PMN, whose responses are noted in Table 1. This discrepancy reflects the daily variability of the assay. To control this variability, paired observations were made such that PMN from one endotoxin-injected rabbit and one saline-injected rabbit were each tested in the same day's assay.

As shown in Fig. 2, after a short initial latency in responsiveness, superoxide production appeared to be linear for PMN obtained after either an LPS or saline injection. The rate of production or slope differs in the two curves, but the linearity of the response is preserved.

| Source of PMN | LPS-Injected | Saline-Injected |
|---------------|--------------|-----------------|
| C5a (1 percent) ($n = 8$) | 1.4 ± 0.6 | 5.6 ± 1.3 |
| PMA (10 ng/ml) ($n = 9$) | 40.8 ± 7.8 | 10.1 ± 1.6 |
| FMLP ($10^{-7}$M) ($n = 6$) | 8.2 ± 3.3 | 9.7 ± 1.6 |

Data expressed as nmol cytochrome C reduced/20 minutes.
ROSENBAUM AND ENKEL

ENDOTOXIN ENHANCES O₂ PRODUCTION IN RESPONSE TO PMA OVER A WIDE RANGE OF CONCENTRATIONS

![Graph showing O₂ release in response to different concentrations of PMA](image)

FIG 1. PMN from endotoxin-injected rabbits released greater amounts of superoxide at each concentration of PMA tested. For both PMN from endotoxin-injected rabbits and from saline-injected controls, increasing PMA from 100 to 300 ng/ml induced only a minimal increment in superoxide release.

DISCUSSION

We have previously demonstrated that intravenously injected LPS results in stimulus-specific changes in rabbit PMN [4–6]. Stimulus-specific changes have been characterized relative to receptor number and functional alterations in chemotaxis and degranulation [4–6]. Recently in clinical studies stimulus-specific changes in PMN function, including a depressed chemotactic response to C5a, have been noted in such diverse disorders as burns and inflammatory skin disease [8,9]. The present study extends our previous observations by considering the effect of intravenous LPS on the ability of PMN to generate superoxide in response to soluble stimuli.

Similar to the observations of Guthrie and colleagues [1], we find that LPS can markedly enhance the release of O₂⁻ by PMN. Our observations, however, are in contrast to previous studies in that we have studied a system that involves in vivo exposure to LPS, and we find that the enhancement of O₂⁻ production is highly stimulus-specific. Using PMA as a stimulus, intravenous LPS appears to enhance O₂⁻ release independent of the dose of PMA or of the time point studied. In contrast, intravenous LPS reduced responsiveness to C5a and did not alter responsiveness to
FMLP. The reduced response to C5a without comparable change in response to FMLP is also seen for chemotaxis, degranulation, and dermal vascular permeability [4,5].

A number of mechanisms might contribute to these observations. Direct binding of LPS, synthesis of soluble factors such as tumor necrosis factor, down regulation of receptors for the chemotactic ligand caused by the generation of chemotactic factors, and demargination of subpopulations of PMN could each contribute to the effects of LPS on PMN, as we have previously noted [4,5]. The alteration of PMN function after *in vivo* exposure to LPS supports the likelihood that this effect is physiologic. It may account in part for the enhanced oxidative metabolism (as measured by chemiluminescence, O$_2^-$ release, or nitro-blue tetrazolium reduction) that has been noted in association with bacterial infection by some investigators [10-12].

Since intravenous LPS down regulates the receptor for C5a [6], the LPS-induced reduction in O$_2^-$ release in response to this ligand may at least in part reflect a receptor-determined change. Since intravenous LPS markedly increases the number of receptors for FMLP [6] without enhancing O$_2^-$ release in response to that stimulus, however, it appears that additional subsequent post-receptor events must be rate-limiting. Furthermore, since O$_2^-$ release in response to PMA is enhanced by intravenous LPS, the post-receptor regulation of superoxide release may differ for PMA and FMLP. Other investigators have reported that discrepant intracellular events appear to determine PMN responses to chemotactic ligands, as opposed to responses to PMA. Pertussis toxin, for example, an inhibitor of the guanosine triphosphate binding protein, N$_i$, inhibits granule release in response to C5a and FMLP, but not in response to PMA [13]. In guinea pig PMN, FMLP induces the breakdown of phosphatidylinositol 4,5 biphosphate and the subsequent formation of diacylglycerol, phosphatidic acid, and free arachidonic acid. PMA fails to induce the breakdown of phosphatidylinositol 4,5 biphosphate or the release of arachidonate [14]. A recent study indicates that a phagocytosable stimulus induces O$_2^-$ release through a different pathway, in comparison to PMA [15]. Different intracellular pathways or differential activation of regulatory substances that control the same metabolic pathway could conceivably account for discordant effects on O$_2^-$ release in response to different stimuli. This hypothesis could account for the ability of LPS to enhance or suppress O$_2^-$ release, depending upon the stimulus studied.

![THE RATE OF O$_2^-$ RELEASE](image)

**FIG. 2.** PMN from LPS-treated rabbits and from controls both released superoxide in an apparently linear fashion after an initial lag period; 10 ng/ml PMA was used as a stimulus. Data are from a single experiment representative of three.
ACKNOWLEDGEMENTS

This work was supported in part by the Northern California Arthritis Foundation, the Pacific Presbyterian Medical Center Department of Medicine, the Medical Research Foundation of Oregon, and a grant from the National Institutes of Health, EY06477.

Dr. Rosenbaum is a Dolly Green Scholar of Research to Prevent Blindness.

Mary Williams provided invaluable secretarial assistance.

REFERENCES

1. Guthrie LA, McPhail LC, Henson PM, Johnston RB: Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. J Exp Med 160:1656–1671, 1984
2. Proctor RA: Endotoxin in vitro interactions with human neutrophils: Depression of chemiluminescence, oxygen consumption, superoxide production, and killing. Infect Immun 25:912, 1979
3. Henricks PAJ, van der Tol ME, Thyszen R M, van Asbeck BS, Verhoef J: Escherichia coli lipopolysaccharides diminish and enhance cell function of human polymorphonuclear leukocytes. Infect Immun 41:294–301, 1983
4. Rosenbaum JT, Hartiala KT, Webster RO, Howes EL Jr, Goldstein IM: Anti-inflammatory effects of endotoxin. Inhibition of rabbit polymorphonuclear leukocyte responses to complement (C5)-derived peptides in vivo and in vitro. Am J Pathol 113:291–299, 1983
5. Hartiala KT, Langlois L, Goldstein IM, Rosenbaum JT: Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors. Infect Immun 50(2):527–533, 1985
6. Goldman DW, Enkel H, Gifford LA, Chenoweth DE, Rosenbaum JT: Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucyl-phenylalanine on rabbit polymorphonuclear leukocytes. J Immunol 137:1971–1976, 1986
7. Johnston RB Jr, Keely BB Jr, Misra HP, Lehmeier JE, Webb LS, Baehner RL, Rajayopalan KV: The role of superoxide anion generation in phagocytic bactericidal activity. J Clin Invest 55:1357–1372, 1975
8. Schroder J-M, Christophers E: Transient absence of C5a-specific neutrophil function in inflammatory disorders of the skin. J Invest Derm 85:194–198, 1985
9. Moore FD, Davis C, Rodrick M, Mannick JA, Fearon DT: Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 314:948–953, 1986
10. Barbour AG, Allred CD, Solberg CD, Hill HR: Chemiluminescence by polymorphonuclear leukocytes from patients with active bacterial infection. J Inf Dis 141:14–26, 1980
11. McCall CE, Bass DA, DeChatelet LR, Link AS, Mann M: In vitro responses of human neutrophils to N-formyl-methionyl-leucyl-phenylalanine: correlation with effects of acute bacterial infection. J Inf Dis 140:277–286, 1979
12. McCall CE, DeChatelet LR, Cooper MR, Shannon C: Human toxic neutrophils. III. Metabolic characteristics. J Inf Dis 127:26–33, 1973
13. Becker AE, Kermode JC, Naccache PH, Yassin R, Marsh ML, Munoz JJ, Sha’afi RI: The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin. J Cell Biol 100:1641–1646, 1985
14. Takenawa T, Ishitoya J, Homma Y, Kato M, Nagai Y: Role of enhanced inositol phospholipid metabolism in neutrophil activation. Biochem Pharm 34:1931–1935, 1985
15. Maridonneau-Parini I, Tringale SM, Tauber AI: Identification of distinct activation pathways of the human neutrophil NADPH-oxidase. J Immunol 137:2925–2929, 1986